A
Apellis Pharmaceuticals D
D
APLS
40.835
USD
-0.02
(-0.04%)
مغلق
حجم التداول
155,286
الربح لكل سهم
-1
العائد الربحي
-
P/E
227
حجم السوق
5,220,413,043
المقالات
العنوان: Apellis Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).